MedTrace Logo

Antihypertensive Medications and the Risk of Sepsis

NCT02248896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1129062

Last updated 2014-09-25

No results posted yet for this study

Summary

The primary objective of this study was to assess whether there is an increased risk of sepsis with the use of telmisartan compared with other ARBs and with the other major antihypertensive classes, including ACEIs, beta-blockers, CCBs and thiazide diuretics. A secondary objective was to assess whether the use of ARBs and ACEIs, compared with the other three major antihypertensive classes and with untreated hypertension, is associated with an increased risk of sepsis. A third objective was to evaluate whether the use of telmisartan compared with other ARBs, ACEIs and other major antihypertensive classes is associated with an increased risk of worse outcomes due to sepsis, in particular acute kidney injury and death

Conditions

Interventions

DRUG

Telmisartan

DRUG

Other angiotensin-receptor blockers (ARBs)

DRUG

Angiotensin-converting enzyme inhibitors (ACEIs)

DRUG

Other major antihypertensive medication classes

e.g. beta-blockers, calcium channel blockers (CCBs), diuretics

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02248896 on ClinicalTrials.gov